LCM
ALNY icon

Laurion Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Laurion Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-17,500
Closed -$1.27M – 832
2018
Q4 		$1.27M Buy
+17,500
New +$1.35M 0.02% 503

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Laurion Capital Management's ALNY Position: Q2 2026 in Review

Laurion Capital Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 23% in Q2 2026, selling an estimated $314K and leaving 3,391 shares worth $1.02M. The position accounts for 0.03% of the portfolio, ranked #246.

Laurion Capital Management first reported a position in ALNY in Q4 2016 and has held it in 6 quarters since. The position peaked at $15.5M in Q4 2017. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Laurion Capital Management held 3,391 shares of Alnylam Pharmaceuticals worth $1.02M as of Q2 2026.
  • Laurion Capital Management sold 1,040 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $314K.
  • Alnylam Pharmaceuticals made up 0.03% of Laurion Capital Management's portfolio in Q2 2026, its #246 holding.
  • Laurion Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2016 and has held it in 6 quarters since.
  • Laurion Capital Management's Alnylam Pharmaceuticals position peaked at $15.5M in Q4 2017.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.